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First experience of pancreaticoduodenectomy using 
Revo-i in a patient with insulinoma
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Robotic surgery systems have been developed to overcome the limitations of laparoscopic surgery. Recently, Meere-
company Inc. in Korea successfully manufactured a robotic surgical system called Revo-i. A 65-year old woman was 
referred for a pancreatic head tumor, detected as an incidental finding during a routine check-up. Contrast abdomi-
nopelvic CT revealed a pancreatic uncinate tumor measuring around 13 mm in diameter, with no other focal lesions. 
The patient underwent a robot-assisted pancreaticoduodenectomy (laparoscopic resection and robotic reconstruction) 
using Revo-i. The patient’s recovery was uneventful and discharged on postoperative day 7. Our case showed the 
technical feasibility of the Korean robotic surgical system Revo-i. Further experiences are mandatory to validate this 
finding. (Ann Hepatobiliary Pancreat Surg 2020;24:104-108)
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INTRODUCTION
Since the introduction of laparoscopic pancreaticoduo-
denectomy (LPD) in 1994 by Gagner and Pomp,1 many 
studies have demonstrated its safety and feasibility.2-4 
However, owing to the technical complexity of the proce-
dure, surgeons require sufficient training to develop skills 
for laparoscopic surgery.5,6 
In general, PD comprises resection and reconstruction. 
Several issues are associated with the resection and re-
construction phases of LPD.7 Particularly, in benign and 
low-grade malignant tumors of the pancreas requiring PD, 
the remnant pancreas is associated with soft pancreas and 
small pancreatic ducts, which is the biggest risk factor for 
postoperative pancreatic fistula (POPF).8-10 Laparoscopic 
reconstruction of the remnant pancreas following the lapa-
roscopic resection of the pancreaticoduodenal component 
is difficult. Skillful techniques and long surgical experi-
ence are required. Hence, a robotic surgical system may 
improve the surgical performance, safety, and effective-
ness.
Robotic surgery has overcome the limitations of laparo-
scopic surgery.11 The advantages of robotic surgery, such 
as a minimized fulcrum effect, three-dimensional oper-
ative view, unrestricted instrument motion, and no invol-
untary tremors, enable surgeons to perform the surgery 
with ease and comfort.12,13 However, the high cost of a 
robotic surgical system is a great obstacle to its applica-
tion in clinical practice, as only the commercial da Vinci 
Surgical System is available.
Fortunately, several robotic surgical systems have been 
developed to date.14-17 Recently, Meerecompany Inc. in 
Korea successfully manufactured a robotic surgical system 
called Revo-i. In recent studies, Chang et al.18 and Kang 
et al.19 performed robotic prostatectomy and cholecystect-
omy, respectively, using Revo-I, without any serious com-
plications in the first human clinical trial. Finally, Revo-i 
was commercialized after obtaining the approval from the 
Korean Food and Drug Administration (KFDA).
Lately, we successfully conducted a robot-assisted min-
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Fig. 1. Preoperative imaging. (A)
Contrast abdominopelvic com-
puted tomography revealed pan-
creatic uncinate tumor measuring
around 13 mm in diameter, 
with no other focal lesions. (B) 
Positron emission tomography- 
computed tomography Ga-68 
DODTATOC demonstrated signi-
ficant focal intense DOTATOC 
uptake in the uncinate process 
of pancreas, suggesting neuro-
endocrine tumor.
imally invasive PD (laparoscopic resection and robotic re-
construction) using Revo-i. Here, we report our first expe-
rience with Revo-i PD in a patient with insulinoma and 




A 65-year-old woman was referred to our hospital for 
a pancreatic head tumor, detected as an incidental finding 
during a routine check-up. The patient had been treated 
for hypertension and had no family history of cancer. How-
ever, she reported of frequent neuroglycopenic symptoms 
during fasting conditions. There were no physical abnor-
malities, and her body mass index was 26.04 kg/m2. The 
laboratory data indicated a slight elevation of the level of 
insulin to 25.47 IU/ml (reference range: 1.0-10.7) and 
C-peptide to 4.60 ng/ml (reference range: 0.6-2.3), but no 
other abnormal findings. The tumor marker values were 
within the normal ranges: carcinoembryonic antigen 0.97 
ng/ml and cancer antigen 19-9, 7.6 U/ml. Preoperative 
imaging (Fig. 1) revealed a pancreatic uncinate process tu-
mor measuring 13 mm with no other significant focal le-
sions, suggesting a neuroendocrine tumor. 
Surgical procedure
The patient underwent surgery on December 21, 2018. 
She was placed in a supine position. The surgery con-
sisted of two processes: laparoscopic resection and robotic 
reconstruction. The laparoscopic resection technique used 
in our institution had been previously published.20 The to-
tal operation time for laparoscopic resection was 3 hours 
and 30 minutes, and the Revo-i robotic surgical system 
was docked (Fig. 2A). Revo-i-assisted pancreaticojejunos-
tomy (PJ) with a double-layered duct-to-mucosa anasto-
mosis (4 inner interrupted sutures for pancreatic duct less 
than 2 mm with a short stent and all interrupted sutures 
for the outer layer of PJ) (Fig. 2B) and choledochojejunos-
tomy (CJ) (posterior continuous and anterior interrupted 
sutures using 4-0 absorbable sutures for 8 mm of remnant 
bile duct reconstruction) were performed (Fig. 2C), which 
took about 4 hours. The total operation time was noted 
to be 514 minutes. The estimated blood loss was 200 ml. 
No intraoperative transfusions were required. After the de-
livery of the specimen through the small, vertical, extend-
ed umbilical wound, duodenojejunostomy was performed 
manually. Two-armed closed suction drains were inserted 
around the anastomosis sites.
Postoperative course
The postoperative course was uneventful, except for 
mild fever. Her surgical drains were removed on post-
operative day 5. A follow-up computed tomography (CT) 
was performed on postoperative day 7. Scant fluid along 
the PJ site was noted on CT. The patient was discharged 
10 days after the operation, without any complications. 
Pathological examination
The pathological diagnosis was neuroendocrine tumor 
(NET), measuring 11 mm in size (Fig. 2D). The mitotic 
count was 1 per 10 high-power fields, and the Ki-67 label-
ing index was 3/760 (0.4%). These results indicated Grade 
1 NET based on the 2017 World Health Organization 
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Fig. 2. Intraoperative and pathological findings. Pa, pancreas; Pd, pancreatic duct; BD, bile duct.
classification. No lymphovascular invasions were detected. 
A total of 6 lymph nodes were harvested, with no lymph 
node metastases. All the resection margins were negative. 
DISCUSSION
The robotic surgery system has gained popularity be-
cause of various advantages over the laparoscopic surgery. 
It enables a more delicate and finer procedure. Further-
more, robotic surgeries show decreased postoperative 
morbidity and hospital stay and faster recovery of patients 
compared to the open approaches.21 They have now been 
widely applied in abdominal surgeries. According to the 
2016 Intuitive Surgical Annual Report, there are over 3700 
robotic surgical systems worldwide and over 3,000,000 
robotic surgeries have been performed.22 Robotic pan-
creaticoduodenectomy is also feasible and safe in select 
patients.23-25 However, the high medical costs of robotic 
surgery, which have been an impediment to their develop-
ment and evolution, have been constantly discussed.25-27 
New robotic surgery systems with lower medical costs are 
required. 
The Meerecompany Inc. has been developing a new ro-
botic surgical system called Revo-i in Korea since 2006. 
Several preclinical studies have been conducted on robotic 
surgery using Revo-i in a porcine model.19,28-30 Kang et al.19 
and Lim et al.30 simultaneously verified the safety and ef-
ficacy of robotic cholecystectomy performed using Revo-i 
in a preclinical experiment. Abdel Raheem et al.29 also 
showed the feasibility of fallopian tube surgery using Revo-i 
in a preclinical chronic porcine model. Owing to these re-
sults, the Revo-i received approval for clinical use from 
the KFDA in 2016. In the first clinical trial of Revo-i, Chang 
et al.18 successfully carried out 17 robotic surgeries on pa-
tients with localized prostate cancer, without any serious 
complications. In addition, Kang et al.19 performed suc-
cessful Revo-i cholecystectomy in the first human clinical 
trial. Based on these positive perioperative outcomes in 
the human clinical trials of Revo-i, it was commercially 
licensed in August 2017. 
In a previous study, the Revo-i characteristics were com-
pared to the da Vinci Surgical System.30 The da Vinci 
Surgical System differed mainly with regard to energy 
sources. Currently, Revo-i has only mono-polar and bi-po-
lar energy delivery systems. Therefore, Revo-i can be ef-
fectively used in the reconstruction phase of PD, but not 
in the resection phase, which requires fine dissection and 
rapid hemostasis. The next generation of Revo-i would be 
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equipped with energy devices, such as vessel sealers and 
harmonic scalpels. 
To the best of our knowledge, this is the first report 
of PPPD performed using Revo-I, which is an alternative 
robotic surgical system for the da Vinci Surgical System. 
In a previous human clinical trial of Revo-i cholecys-
tectomy and prostatectomy, it was found technically fea-
sible and safe in performing delicate and complex surgical 
procedures, such as PJ in remnant pancreas with a pancre-
atic duct shorter than 2 mm and CJ in a remnant bile duct 
smaller than 1 cm. The articulating movement of a robotic 
instrument and effective third-arm intervention are useful 
during the reconstruction phase of PD. However, for a 
safer and more reliable clinical application of Revo-i in 
advanced minimally invasive surgeries, improving the du-
rability and fine tuning of robotic instruments and quality 
of vision should be mandatory. An additional clinical trial 
to investigate the safety of Revo-i in advanced minimally 
invasive hepatobiliary and pancreatic surgery should be 
performed.
In summary, we have successfully performed PD using 
Revo-i to treat a patient with insulinoma of the pancreatic 
uncinate process. This case demonstrated the technical fea-
sibility of the Korean robotic surgical system Revo-i. We 
hope that other robotic systems would be developed to 
overcome the current limitations regarding cost effective-
ness and to provide high-quality, minimally invasive sur-
geries in the near future.
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